Prescription patterns following first-line new generation antidepressants for depression in Japan: A naturalistic cohort study based on a large claims database

Journal of Affective Disorders

Volumn 150, Issue 3, 2013, Pages 916-922

  Furukawa, Toshi A ^a   Onishi, Yoshie ^a   Hinotsu, Shiro ^a   Tajika, Aran ^a   Takeshima, Nozomi ^a   Shinohara, Kiyomi ^a   Ogawa, Yusuke ^a   Hayasaka, Yu ^a   Kawakami, Koji ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antidepressive agents; Depressive disorder; Drug administration schedule; Patient compliance

Indexed keywords

AMOXAPINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; DULOXETINE; FLUVOXAMINE; MILNACIPRAN; MIRTAZAPINE; PAROXETINE; PSYCHOTROPIC AGENT; SERTRALINE; SULPIRIDE; TRAZODONE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; COHORT ANALYSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEALTH INSURANCE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MAXIMUM PERMISSIBLE DOSE; PRESCRIPTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; TREATMENT DURATION;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; PATIENT COMPLIANCE;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; COHORT STUDIES; DATABASES, FACTUAL; DEPRESSIVE DISORDER, MAJOR; DRUG PRESCRIPTIONS; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84888359803     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2013.05.015     Document Type: Article

References (24)

1. American Psychiatric Association, 2010. Practice guideline for the treatment of patients with major depressive disorder, third ed.American Journal of Psychiatry, 167. American Psychiatric Association pp. 1-152.
2. Bauer, M., Monz, B.U., Montejo, A.L., Quail, D., Dantchev, N., Demyttenaere, K., Garcia-Cebrian, A., Grassi, L., Perahia, D.G., Reed, C., Tylee, A., 2008. Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study. European Psychiatry 23, 66-73.
3. Bollini, P., Pampallona, S., Tibaldi, G., Kupelnick, B., Munizza, C., 1999. Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. British Journal of Psychiatry 174, 297-303.
4. Cipriani, A., Furukawa, T.A., Salanti, G., Geddes, J.R., Higgins, J.P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I.M., McGuire, H., Tansella, M., Barbui, C., 2009. Comparative efficacy and acceptability of 12 new-generation antidepres-sants: a multiple-treatments meta-analysis. Lancet 373, 746-758.
5. Fredman, S.J., Fava, M., Kienke, A.S., White, C.N., Nierenberg, A.A., Rosenbaum, J.F., 2000. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. Journal of Clinical Psychiatry 61, 403-408.
6. Furukawa, T., Cipriani, A., Barbui, C., Geddes, J., 2007. Long-term treatment of depression with antidepressants: a systematic narrative review. Canadian Journal of Psychiatry-Revue Canadienne De Psychiatrie 52, 545-552.
7. Furukawa, T., Kitamura, T., Takahashi, K., 2000. Treatment received by depressed patients in Japan and its determinants: naturalistic observation from a multicenter collaborative follow-up study. Journal of Affective Disorders 60, 173-179.
8. Furukawa, T.A., Akechi, T., Shimodera, S., Yamada, M., Miki, K., Watanabe, N., Inagaki, M., Yonemoto, N., 2011. Strategic Use of New generation antidepressants for Depression: SUN(\widehat\widehat)D study protocol. Trials 12, 116.
9. Geddes, J.R., Carney, S.M., Davies, C., Furukawa, T.A., Kupfer, D.J., Frank, E., Goodwin, G.M., 2003. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361, 653-661.
10. Japanese Society of Mood Disorders, 2012. Japanese Society of Mood Disorders Practice Guideline II: Major depressive disorder.
11. Lam, R.W., Kennedy, S.H., Grigoriadis, S., McIntyre, R.S., Milev, R., Ramasubbu, R., Parikh, S.V., Patten, S.B., Ravindran, A.V., 2009. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. Journal of Affective Disorders 117 (Suppl. 1), S26-43.
12. Marcus, S.C., Hassan, M., Olfson, M., 2009. Antidepressant switching among adherent patients treated for depression. Psychiatric Services 60, 617-623.
13. Melartin, T.K., Rytsala, H.J., Leskela, U.S., Lestela-Mielonen, P.S., Sokero, T.P., Isometsa, E.T., 2005. Continuity is the main challenge in treating major depressive disorder in psychiatric care. Journal of Clinical Psychiatry 66, 220-227.
14. NICE, 2009. Depression: the treatment and management of depression in adults (partial update of NICE clinical guideline 23). National Institute for Clinical Excellence, London.
15. Olfson, M., Marcus, S.C., Tedeschi, M., Wan, G.J., 2006. Continuity of antidepressant treatment for adults with depression in the United States. American Journal of Psychiatry 163, 101-108.
16. Onishi, Y., Hinotsu, S., Furukawa, T.A., Kawakami, K., Antidepressant prescription patterns among patients with major depression based on claims database in Japan, submitted for publication.
17. Robinson, R.L., Long, S.R., Chang, S., Able, S., Baser, O., Obenchain, R.L., Swindle, R.W., 2006. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims. Journal of Managed Care Pharmacy 12, 43-54.
18. Ruhe, H.G., Huyser, J., Swinkels, J.A., Schene, A.H., 2006a. Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic review. British Journal of Psychiatry 189, 309-316.
19. Ruhe, H.G., Huyser, J., Swinkels, J.A., Schene, A.H., 2006b. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. Journal of Clinical Psychiatry 67, 1836-1855.
20. Sarrazin, M.S., Rosenthal, G.E., 2012. Finding pure and simple truths with administrative data. JAMA: the Journal of the American Medical Association, 307; pp. 1433-1435.
21. Sewitch, M.J., Blais, R., Rahme, E., Bexton, B., Galarneau, S., 2007. Receiving guideline-concordant pharmacotherapy for major depression: impact on ambulatory and inpatient health service use. Canadian Journal of Psychiatry-Revue Canadienne De Psychiatrie 52, 191-200.
22. Sheehan, D.V., Keene, M.S., Eaddy, M., Krulewicz, S., Kraus, J.E., Carpenter, D.J., 2008. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs 22, 963-973.
23. Solberg, L.I., Engebretson, K.I., Sperl-Hillen, J.M., Hroscikoski, M.C., O'Connor, P.J., 2006. Are claims data accurate enough to identify patients for performance measures or quality improvement? The case of diabetes, heart disease, and depression. American Journal of Medical Quality: the Official Journal of the American College of Medical Quality 21, 238-245.
24. PSS Inc., 2009. SPSS for Windows Version 18.0. SPSS Inc., Chicagoo